Letter: Galectin-3: An Important but Insufficiently Explored Biomarker in Cardiovascular Disease

Abstract

Keywords

Galectin-3 biomarker cardiovascular disease

Get full access to this article

View all access options for this article.

References

Köktürk

Püşüroğlu

Somuncu

, et al. Short and Long-Term Prognostic Significance of Galectin-3 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology. 2023;74:889-896.

Tymińska

Kapłon-Cieślicka

Ozierański

, et al. Association of galectin-3 and soluble ST2 with in-hospital and 1-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Pol Arch Intern Med. 2019;129:770-780.

Asleh

Enriquez-Sarano

Jaffe

, et al. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. J Am Coll Cardiol. 2019;73:2286-2295.

Isola

Polizzi

Alibrandi

Williams

Lo Giudice

. Analysis of galectin-3 levels as a source of coronary heart disease risk during periodontitis. J Periodontal Res. 2021;56:597-605.

Tsigkou

Siasos

Oikonomou

, et al. The prognostic role of galectin-3 and endothelial function in patients with heart failure. Cardiol J. 2022. doi:10.5603/CJ.a2022.0074

Ruan

Gao

Wang

, et al. Circulating Galectin-3 and Aldosterone for Predicting Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation. Cardiovasc Ther. 2022;2022:6993904.

Pranata

Yonas

Chintya

Tondas

Raharjo

. Serum Galectin-3 level and recurrence of atrial fibrillation post-ablation - Systematic review and meta-analysis. Indian Pacing Electrophysiol J. 2020;20:64-69.

Kornej

Schmidl

Ueberham

, et al. Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One. 2015;10:e0123574.